EMEA (Europe, Middle East and Africa) Neurological Disorder Drugs Market Report 2017

July 2017 | 106 pages | ID: E5826F71E90EN
QYResearch

Abstracts

In this report, the EMEA Neurological Disorder Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Neurological Disorder Drugs for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Neurological Disorder Drugs market competition by top manufacturers/players, with Neurological Disorder Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Novartis AG
• GlaxoSmithKline plc
• Merck & Co.
• Bayer AG
• AstraZeneca
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into

• Antipsychotic
• Hypnotic & Sedative
• Analgesics
• Anticoagulants
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Pcs), market share and growth rate of Neurological Disorder Drugs for each application, including

• Hospital
• Clinic
• Home

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Neurological Disorder Drugs Market Report 2017

1 NEUROLOGICAL DISORDER DRUGS OVERVIEW

1.1 Product Overview and Scope of Neurological Disorder Drugs
1.2 Classification of Neurological Disorder Drugs
  1.2.1 EMEA Neurological Disorder Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Neurological Disorder Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Antipsychotic
  1.2.4 Hypnotic & Sedative
  1.2.5 Analgesics
  1.2.6 Anticoagulants
  1.2.7 Others
1.3 EMEA Neurological Disorder Drugs Market by Application/End Users
  1.3.1 EMEA Neurological Disorder Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Home
1.4 EMEA Neurological Disorder Drugs Market by Region
  1.4.1 EMEA Neurological Disorder Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Neurological Disorder Drugs (2012-2022)
  1.5.1 EMEA Neurological Disorder Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Neurological Disorder Drugs Revenue and Growth Rate (2012-2022)

2 EMEA NEUROLOGICAL DISORDER DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Neurological Disorder Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Neurological Disorder Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Neurological Disorder Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Neurological Disorder Drugs Sale Price by Players (2012-2017)
2.2 EMEA Neurological Disorder Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Neurological Disorder Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Neurological Disorder Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Neurological Disorder Drugs Sale Price by Type (2012-2017)
2.3 EMEA Neurological Disorder Drugs (Volume) by Application
2.4 EMEA Neurological Disorder Drugs (Volume and Value) by Region
  2.4.1 EMEA Neurological Disorder Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Neurological Disorder Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Neurological Disorder Drugs Sales Price by Region (2012-2017)

3 EUROPE NEUROLOGICAL DISORDER DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Neurological Disorder Drugs Sales and Value (2012-2017)
  3.1.1 Europe Neurological Disorder Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Neurological Disorder Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Neurological Disorder Drugs Sales and Market Share by Type
3.3 Europe Neurological Disorder Drugs Sales and Market Share by Application
3.4 Europe Neurological Disorder Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Neurological Disorder Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Neurological Disorder Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Neurological Disorder Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST NEUROLOGICAL DISORDER DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Neurological Disorder Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Neurological Disorder Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Neurological Disorder Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Neurological Disorder Drugs Sales and Market Share by Type
4.3 Middle East Neurological Disorder Drugs Sales and Market Share by Application
4.4 Middle East Neurological Disorder Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Neurological Disorder Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Neurological Disorder Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Neurological Disorder Drugs Sales and Growth Rate (2012-2017)

5 AFRICA NEUROLOGICAL DISORDER DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Neurological Disorder Drugs Sales and Value (2012-2017)
  5.1.1 Africa Neurological Disorder Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Neurological Disorder Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Neurological Disorder Drugs Sales and Market Share by Type
5.3 Africa Neurological Disorder Drugs Sales and Market Share by Application
5.4 Africa Neurological Disorder Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Neurological Disorder Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Neurological Disorder Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Neurological Disorder Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Neurological Disorder Drugs Sales and Growth Rate (2012-2017)

6 EMEA NEUROLOGICAL DISORDER DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Novartis AG
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Novartis AG Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 GlaxoSmithKline plc
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Merck & Co.
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Merck & Co. Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Bayer AG
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Bayer AG Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 AstraZeneca
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 AstraZeneca Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Boehringer Ingelheim GmbH
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Teva Pharmaceutical Industries Ltd.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Neurological Disorder Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview

7 NEUROLOGICAL DISORDER DRUGS MANUFACTURING COST ANALYSIS

7.1 Neurological Disorder Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Neurological Disorder Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Neurological Disorder Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Neurological Disorder Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA NEUROLOGICAL DISORDER DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Neurological Disorder Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Neurological Disorder Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Neurological Disorder Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Neurological Disorder Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Neurological Disorder Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Neurological Disorder Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Neurological Disorder Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Neurological Disorder Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Neurological Disorder Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Neurological Disorder Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Neurological Disorder Drugs
Figure EMEA Neurological Disorder Drugs Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Neurological Disorder Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Antipsychotic Product Picture
Figure Hypnotic & Sedative Product Picture
Figure Analgesics Product Picture
Figure Anticoagulants Product Picture
Figure Others Product Picture
Figure EMEA Neurological Disorder Drugs Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Neurological Disorder Drugs by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Home Examples
Table Key Downstream Customer in Home
Figure EMEA Neurological Disorder Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Neurological Disorder Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Neurological Disorder Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Neurological Disorder Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Neurological Disorder Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Neurological Disorder Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Neurological Disorder Drugs Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Neurological Disorder Drugs Sales Share by Players (2012-2017)
Figure 2016 Neurological Disorder Drugs Sales Share by Players
Figure 2017 Neurological Disorder Drugs Sales Share by Players
Figure EMEA Neurological Disorder Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Neurological Disorder Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Neurological Disorder Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Neurological Disorder Drugs Revenue Share by Players
Table 2017 EMEA Neurological Disorder Drugs Revenue Share by Players
Table EMEA Neurological Disorder Drugs Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Neurological Disorder Drugs Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Neurological Disorder Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Neurological Disorder Drugs by Type (2012-2017)
Figure EMEA Neurological Disorder Drugs Sales Market Share by Type (2012-2017)
Table EMEA Neurological Disorder Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Neurological Disorder Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Neurological Disorder Drugs by Type in 2016
Table EMEA Neurological Disorder Drugs Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Neurological Disorder Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Neurological Disorder Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Neurological Disorder Drugs by Application (2012-2017)
Figure EMEA Neurological Disorder Drugs Sales Market Share by Application in 2016
Table EMEA Neurological Disorder Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Neurological Disorder Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Neurological Disorder Drugs by Region (2012-2017)
Figure EMEA Neurological Disorder Drugs Sales Market Share in 2016
Table EMEA Neurological Disorder Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Neurological Disorder Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Neurological Disorder Drugs by Region (2012-2017)
Figure EMEA Neurological Disorder Drugs Revenue Market Share Regions in 2016
Table EMEA Neurological Disorder Drugs Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Neurological Disorder Drugs Revenue and Growth Rate (2012-2017)
Table Europe Neurological Disorder Drugs Sales (K Pcs) by Type (2012-2017)
Table Europe Neurological Disorder Drugs Market Share by Type (2012-2017)
Figure Europe Neurological Disorder Drugs Market Share by Type in 2016
Table Europe Neurological Disorder Drugs Sales (K Pcs) by Application (2012-2017)
Table Europe Neurological Disorder Drugs Market Share by Application (2012-2017)
Figure Europe Neurological Disorder Drugs Market Share by Application in 2016
Table Europe Neurological Disorder Drugs Sales (K Pcs) by Countries (2012-2017)
Table Europe Neurological Disorder Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Neurological Disorder Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Neurological Disorder Drugs Sales Market Share by Countries in 2016
Table Europe Neurological Disorder Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Neurological Disorder Drugs Revenue Market Share by Countries in 2016
Figure Germany Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Neurological Disorder Drugs Sales (K Pcs) by Type (2012-2017)
Table Middle East Neurological Disorder Drugs Market Share by Type (2012-2017)
Figure Middle East Neurological Disorder Drugs Market Share by Type (2012-2017)
Table Middle East Neurological Disorder Drugs Sales (K Pcs) by Applications (2012-2017)
Table Middle East Neurological Disorder Drugs Market Share by Applications (2012-2017)
Figure Middle East Neurological Disorder Drugs Sales Market Share by Application in 2016
Table Middle East Neurological Disorder Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Neurological Disorder Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Neurological Disorder Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Neurological Disorder Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Neurological Disorder Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Neurological Disorder Drugs Sales (K Pcs) by Type (2012-2017)
Table Africa Neurological Disorder Drugs Sales Market Share by Type (2012-2017)
Figure Africa Neurological Disorder Drugs Sales Market Share by Type (2012-2017)
Figure Africa Neurological Disorder Drugs Sales Market Share by Type in 2016
Table Africa Neurological Disorder Drugs Sales (K Pcs) by Application (2012-2017)
Table Africa Neurological Disorder Drugs Sales Market Share by Application (2012-2017)
Figure Africa Neurological Disorder Drugs Sales Market Share by Application (2012-2017)
Table Africa Neurological Disorder Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Neurological Disorder Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Neurological Disorder Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Neurological Disorder Drugs Sales Market Share by Countries in 2016
Table Africa Neurological Disorder Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Neurological Disorder Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Neurological Disorder Drugs Revenue Market Share by Countries in 2016
Figure South Africa Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Table Novartis AG Neurological Disorder Drugs Basic Information List
Table Novartis AG Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis AG Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Novartis AG Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis AG Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline plc Neurological Disorder Drugs Basic Information List
Table GlaxoSmithKline plc Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure GlaxoSmithKline plc Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure GlaxoSmithKline plc Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline plc Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table Merck & Co. Neurological Disorder Drugs Basic Information List
Table Merck & Co. Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck & Co. Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Merck & Co. Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure Merck & Co. Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table Bayer AG Neurological Disorder Drugs Basic Information List
Table Bayer AG Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bayer AG Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Bayer AG Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure Bayer AG Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table AstraZeneca Neurological Disorder Drugs Basic Information List
Table AstraZeneca Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AstraZeneca Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure AstraZeneca Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure AstraZeneca Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Basic Information List
Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Basic Information List
Table Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales Market Share in EMEA (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Neurological Disorder Drugs
Figure Manufacturing Process Analysis of Neurological Disorder Drugs
Figure Neurological Disorder Drugs Industrial Chain Analysis
Table Raw Materials Sources of Neurological Disorder Drugs Major Manufacturers in 2016
Table Major Buyers of Neurological Disorder Drugs
Table Distributors/Traders List
Figure EMEA Neurological Disorder Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Neurological Disorder Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Neurological Disorder Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Neurological Disorder Drugs Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Neurological Disorder Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Neurological Disorder Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Neurological Disorder Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Neurological Disorder Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Neurological Disorder Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Neurological Disorder Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Neurological Disorder Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Neurological Disorder Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Neurological Disorder Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Neurological Disorder Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Neurological Disorder Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Neurological Disorder Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Neurological Disorder Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Neurological Disorder Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Neurological Disorder Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Neurological Disorder Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Neurological Disorder Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Neurological Disorder Drugs Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Neurological Disorder Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources